Holdemanella biformis
| Holdemanella biformis | |
|---|---|
| Scientific classification | |
| Domain: | |
| Phylum: | |
| Class: | |
| Order: | |
| Family: | |
| Genus: | Holdemanella
|
| Species: | H. biformis
|
| Binomial name | |
| Holdemanella biformis (Eggerth 1935) De Maesschalck et al., 2014
| |
| Type strain | |
| DSM 3989 | |
Holdemanella biformis is a species of Gram-positive, strictly anaerobic bacteria within the family Erysipelotrichaceae. Initially described as Eubacterium biforme in 1935, it was reclassified into the genus Holdemanella in 2014 based on phylogenetic analyses of 16S rRNA gene sequences.[1]
Morphology and physiology
[edit]Holdemanella biformis cells are rod-shaped, non-spore-forming, and exhibit obligate anaerobic metabolism. They ferment carbohydrates to produce short-chain fatty acids (SCFAs), including butyrate, which plays a crucial role in colonic health by serving as an energy source for colonocytes.
Ecology
[edit]This bacterium is a commensal member of the human gut microbiota, predominantly residing in the colon. Its abundance can vary based on diet, age, and health status. Studies have shown that H. biformis is underrepresented in individuals with colorectal adenomas, suggesting a potential protective role against early stages of colorectal cancer.[2]
Clinical and metabolic significance
[edit]Research indicates that H. biformis may have beneficial effects on host metabolism and inflammation:
- Glucose Metabolism: A 2021 study demonstrated that administration of H. biformis to obese mice improved glucose tolerance, restored gluconeogenesis and insulin signaling in the liver, and enhanced GLP-1 levels and signaling pathways. These effects suggest potential therapeutic applications for metabolic disorders such as type 2 diabetes.[3]
- Anti-inflammatory Properties: H. biformis produces 3-hydroxyoctadecaenoic acid (C18-3OH), a long-chain fatty acid with anti-inflammatory effects. This compound acts as an agonist of peroxisome proliferator-activated receptor gamma (PPARγ), which plays a role in regulating inflammation and energy homeostasis.[4]
See also
[edit]References
[edit]- ^ De Maesschalck, C.; Van Immerseel, F.; Eeckhaut, V.; De Baere, S.; Cnockaert, M.; Croubels, S.; Haesebrouck, F.; Ducatelle, R.; Vandamme, P. (November 2014). "Faecalicoccus acidiformans gen. nov., sp. nov., isolated from the chicken caecum, and reclassification of Streptococcus pleomorphus (Barnes et al. 1977), Eubacterium biforme (Eggerth 1935) and Eubacterium cylindroides (Cato et al. 1974) as Faecalicoccus pleomorphus comb. nov., Holdemanella biformis gen. nov., comb. nov. and Faecalitalea cylindroides gen. nov., comb. nov., respectively, within the family Erysipelotrichaceae". International Journal of Systematic and Evolutionary Microbiology. 64 (11): 3877–3884. doi:10.1099/ijs.0.064626-0. PMID 25180093.
- ^ "In the gut microbiota a new weapon against colon cancer". Bioscience Institute. 3 February 2020. Retrieved 2025-07-02.
- ^ Romaní-Pérez, M.; López-Almela, I.; Bullich-Vilarrubias, C.; Rueda-Ruzafa, L.; Gómez Del Pulgar, E.M.; Benítez-Páez, A.; Liebisch, G.; Lamas, J.A.; Sanz, Y. (2021). "Holdemanella biformis improves glucose tolerance and regulates GLP-1 signaling in obese mice". The FASEB Journal. 35 (7): e21612. doi:10.1096/fj.202100126R. PMID 34143451.
- ^ "Bacteria-derived long chain fatty acid exhibits anti-inflammatory properties". Gut. 70 (6): 1088. 2021. doi:10.1136/gutjnl-2020-321173. PMID 32978245.